Summit Therapeutics (SMMT) Q3 2026 earnings review
Summit secures $2 billion from AstraZeneca while trial costs rise
Summit Therapeutics solved its funding shortage right after the quarter ended while its clinical trial bill kept climbing. The cancer drug developer has no commercial revenue yet, and third-quarter operating costs excluding stock pay rose 61% from a year ago to $167 million as it opened new studies. Cash ended September at $630 million, before AstraZeneca invested $2 billion in October.
| Operating costs, excluding stock pay | $166.9M +61% from a year ago |
|---|---|
| Cash and short-term investments | $629.8M before $2.0B from AstraZeneca in October |
| Phase III clinical trials | 17 up from 15 last quarter |
| HARMONi-3 squamous lung cancer readout | Q4 2026 narrowed from second half of 2026 |
⚖️ Verdict: 🟢 Bullish
The story got better because co-chief executive Robert Duggan secured AstraZeneca's $2 billion investment at $18.36 per share, wiping out the cash crunch that forced a going-concern warning last quarter. Partner Akeso also reported statistically significant survival wins in two Chinese Phase III trials, and the global Phase III study count rose from 15 to 17. One caution: the cash burn reached $160 million in the third quarter by our math, and the FDA's November 14 decision still hangs on a survival requirement the first global trial missed in its primary test.
The question now is whether the FDA approves ivonescimab on November 14 and whether the larger HARMONi-3 first-line lung cancer trial succeeds later this quarter. Regulators may accept the updated 24% death-risk reduction as enough evidence, or they may reject the application because the primary survival test missed statistical significance. The November 14 decision and the fourth-quarter HARMONi-3 readout will settle both debates.
🐂 Bull Case
AstraZeneca's $2 Billion Investment Ends Cash Concerns
Summit Therapeutics is a cancer drug developer testing ivonescimab, an experimental antibody that blocks two tumour growth pathways at once. Last quarter, the company warned that its cash would not last a full year and that its share-sale programme was empty. In October, British drugmaker AstraZeneca invested $2.0 billion in preferred shares that convert into common stock at $18.36 per share.
- Cash and short-term investments at September 30: $629.8 million
- Cash including AstraZeneca's October investment: $2.63 billion by our math
- Share sales on the open market in the third quarter: $94.1 million
- New shares from AstraZeneca's investment if converted: 109 million, a 13.7% increase by our math
This cash injection removes the funding shortage that hung over the business. By our math, $2.63 billion covers more than 16 quarters of cash use at the third quarter's pace of $159.8 million. It also avoids a cut-price share sale around the November regulatory decision, though existing owners still take dilution.
What to watch: the quarterly filing's liquidity note. Removing the formal going-concern warning will confirm that management expects the new cash to fund all current late-stage trials.
Late-Stage Trial Count Grows Alongside New Partnerships
"Our global clinical development program for ivonescimab continues to broaden," co-chief executive Maky Zanganeh said. For three straight quarters, the total number of Phase III trials — the large final studies needed for drug approval — had stayed at 15 while smaller investigator-led studies grew. This quarter, the Phase III count rose to 17.
The biotech group started enrolling patients in HARMONi-GU1, a Phase II/III bladder cancer trial, and partnered on EA2251, a biliary tract cancer study. It also signed deals to test its drug alongside cancer medicines from AstraZeneca and Japanese drugmaker Daiichi Sankyo, where each partner supplies its own drug and shares trial costs because "The collaboration does not include upfront payments, milestone payments, or royalty sharing provisions".
What to watch: the announcement of a Phase III breast cancer study with AstraZeneca and Daiichi Sankyo's drug Datroway. Starting that trial will show the partnership is creating new late-stage registration paths.
China Trials Beat Standard Treatments on Survival
Summit licensed ivonescimab from Chinese biotech Akeso, which runs its own trials in China. Investors watch those studies to see whether slowing tumour growth translates into patients living longer — known as overall survival — and whether results in Asia hold up in Western patients.
In September, Akeso's HARMONi-2 lung cancer study showed a "statistically significant and clinically meaningful improvement compared to pembrolizumab monotherapy", cutting the risk of death by 27% against Merck's standard treatment. In October, Akeso's biliary tract cancer trial beat AstraZeneca's durvalumab plus chemotherapy, cutting the risk of death by 25%. Meanwhile, longer follow-up in Summit's own global HARMONi trial showed "western patients replicated the survival improvement seen in Asian patients", with both groups showing a 24% lower risk of death.
What to watch: the first readout from the global HARMONi-3 lung cancer trial in the fourth quarter of 2026. A win there would prove the drug can beat standard treatments in a global study, not just in China.
🐻 Bear Case
First US Approval Faces a Survival Hurdle
The company is waiting for the US Food and Drug Administration (FDA) to rule by November 14, 2026 on its application to sell ivonescimab for a specific type of lung cancer after earlier treatment fails. Management says the drug has a favourable benefit-risk profile and points to updated data from June 2026 showing a 24% reduction in the risk of death.
That argument cuts against the regulator's own rule. In the release, the group repeats that "the FDA noted that a statistically significant OS benefit is necessary to support marketing authorization in this setting". In the primary analysis where the statistical test was formally spent, the survival benefit missed that bar. Later updates showing a 0.76 hazard ratio — meaning a 24% lower death risk — are follow-up snapshots that do not retroactively pass the original test, and Johnson & Johnson's amivantamab is already approved for these patients.
What to watch: the FDA decision on or around November 14, 2026. A rejection letter would leave the drug developer with no commercial revenue in 2027 and make the thesis wait for the HARMONi-3 trial.
Clinical Trial Expansion Drives Cash Burn Higher
On standard accounting rules, the quarter's net loss shrank 10% from a year ago to $208.4 million. That drop happened only because last year included a large one-off charge for modifying executive stock options. Excluding stock pay, operating expenses rose 61.4% to $166.9 million as the developer ran more global trials.
- Research and development excluding stock pay: $145.2 million, up 60.4% from a year ago
- General and administrative costs excluding stock pay: $21.7 million, up 68.2% from a year ago
- Nine-month operating cash outflow: $423.2 million, up 91.5% from $221.0 million a year ago
- Third-quarter operating cash outflow: $159.8 million by our math, up from a $131.7 million quarterly average in the first half
Because the company is starting new bladder, kidney and colorectal cancer studies at the same time, cash outflow is rising every quarter.
What to watch: fourth-quarter operatingexpenses excluding stock pay. Another step-up will show how quickly the new Phase II and Phase III trials are eating into the AstraZeneca cash.
Risks this quarter didn't answer
Summit skipped a regular earnings call this quarter and will hold a webcast after the November 14 FDA decision, leaving three standing concerns without an update.
- Commercial launch preparation: with the FDA decision 10 days away, the release gave no sales-force headcount, launch budget or commercial inventory numbers; the post-decision conference call is the next test.
- Dependence on Akeso: all value still rests on one licensed drug where Akeso controls the Chinese studies and is owed milestone payments and royalties; the quarterly filing will show any milestone updates.
- Long-term revenue assumptions: management has previously cited $15 billion in peak sales by 2033 without giving pricing or patient share figures, and the release added no breakdown.
💲 Other KPIs
The average share count rose 7.4% from 743.4 million a year ago and 2.6% from 778.2 million last quarter. Summit sold shares through its open-market facility during the summer to fund clinical trials. This third-quarter count does not yet include the 109 million shares convertible from AstraZeneca's October investment.
Total liabilities climbed 38.9% from $92.3 million at the end of 2025 and rose from $122.2 million in the second quarter. The oncology company carries no debt, so the increase comes from higher accrued clinical trial and operating payables as global studies expand.
Stock pay fell by $83.1 million from $130.8 million a year ago, and dropped from $68.7 million in the second quarter. The decline is a base effect because the drug developer modified executive stock options in the second quarter of 2025, creating huge non-cash charges that are now fading.
🔮 Guidance
Unchanged. The company narrowed the timing for reaching the required number of progression-free survival events — patients whose cancer has not worsened — from the second half of 2026 to the fourth quarter of 2026. An early interim look at overall survival will happen at the same time.
Unchanged. Both cohorts of the global first-line lung cancer study have finished enrolling patients. Management still expects to reach the required event counts for the non-squamous progression-free survival analysis and a separate squamous overall survival analysis in the first half of 2027.
New. The global Phase III colorectal cancer trial is enrolling faster than initial internal estimates and is now expected to finish enrolling 900 patients in the third quarter of 2027. Last year, the trial was initially set to enroll 600 patients.
Unchanged. The kidney cancer study combining ivonescimab with Arcus Biosciences' drug casdatifan is still expected to produce initial data by the middle of 2027.
❓ Key Questions
What is the commercial launch budget and sales-force size?
With the November 14 FDA decision date days away, Summit has still not given a sales-force headcount or launch cost budget for its first lung cancer indication.
Will Summit publish the HARMONi-3 fourth-quarter data immediately?
The squamous lung cancer cohort reaches its primary analysis in the fourth quarter, and management previously said a press release with survival curves for investors was not a high priority.
What milestone payment is owed to Akeso upon FDA approval?
Approval on November 14 would trigger regulatory milestone payments to licensing partner Akeso, and the release does not state how much cash would be due immediately.
What commercial rights or protections did AstraZeneca receive?
The forward-looking statements mention AstraZeneca's contractual rights, including third-party acquisition participation, which investors need detailed to understand if a future buyout by another drugmaker is restricted.